Hypera Pharma Sustainability Profile
Hypera Pharma, a leading player in the Brazilian pharmaceutical industry, is headquartered in São Paulo, Brazil. Founded in 2010, the company has rapidly established itself as a key provider of prescription and over-the-counter medications, focusing on therapeutic areas such as central nervous system disorders, dermatology, and consumer health. With a diverse portfolio of well-known brands, Hypera Pharma distinguishes itself through its commitment to innovation and quality, ensuring that its products meet the highest standards. The company has achieved significant market presence, becoming one of the largest pharmaceutical companies in Brazil, and has garnered recognition for its strategic acquisitions and robust growth trajectory. Hypera Pharma continues to enhance its position in the industry by prioritising research and development, aiming to improve health outcomes for patients across the region.
DitchCarbon Score
How does Hypera Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hypera Pharma's score of 30 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hypera Pharma's reported carbon emissions
In 2024, Hypera Pharma reported total carbon emissions of approximately 50.2 million kg CO2e. This figure encompasses all scopes of emissions, although specific breakdowns for Scope 1, Scope 2, and Scope 3 emissions were not disclosed for this year. Hypera Pharma has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030, using 2020 as the baseline year. This target has been validated by the Science Based Targets initiative (SBTi) and reflects the company's commitment to align with the 1.5°C climate goal. Additionally, Hypera Pharma is focused on measuring and reducing its Scope 3 emissions, although specific targets for these emissions have not been detailed. The company has demonstrated a commitment to reducing its emissions intensity, with reported reductions in Scope 1 emissions intensity of approximately 2.6% in 2024 and 2.8% in 2023. These efforts are part of Hypera Pharma's broader strategy to enhance sustainability and mitigate climate impact. Hypera Pharma's emissions data is sourced directly from Hypera S.A., with no cascaded data from parent or related organizations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | |
|---|---|---|
| Scope 1 | 23,726,750 | 00,000,000 |
| Scope 2 | 3,852,990 | 0,000,000 |
| Scope 3 | 17,223,730 | 00,000,000 |
How Carbon Intensive is Hypera Pharma's Industry?
How Carbon Intensive is Hypera Pharma's Location?
Hypera Pharma's Scope 3 Categories Breakdown
Hypera Pharma's Scope 3 emissions, which decreased by 6% last year and decreased by approximately 6% since 2020, demonstrating supply chain emissions tracking. A significant portion of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 32% of total emissions under the GHG Protocol, with "Employee Commuting" being the largest emissions source at 13% of Scope 3 emissions.
Top Scope 3 Categories
Hypera Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hypera Pharma has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Hypera Pharma's sustainability data and climate commitments
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.